Key facts
- PhAST’s last known valuation is $241.7M (Apr 2025).
- It has raised $18.6M; the latest was Later Stage VC ($3.5M) in Apr 2025.
- Notable investors include Endless Frontier Labs, Labcorp Venture Fund, DAYLI Partners, BlueLion Incubator, Laboratory Corporation of America — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for PhAST
- ·The full record, as it builds
Funding rounds
No funding rounds for PhAST are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PhAST
Developer of an imaging technology designed to transform the fight against infectious diseases. The company's technology uses artificial intelligence and machine learning to harness the immediate and extensive information that imaging reveals about pathogens, enabling healthcare providers to improve patient recovery.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2016
- Employees
- 28
- Website
- phast.ai/
- Ownership
- Privately Held (backing)
PhAST doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PhAST shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PhAST in its N-PORT filings yet. We sweep new filings monthly.